Immutep Ltd (YP1B) AI Stock Analysis

0 Followers

Immutep Ltd

(Frankfurt:YP1B)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and Gross Margin ImprovementThe sharp FY2026 revenue increase indicates improving commercial traction, while the approximately 83% gross margin shows that growth can generate meaningful gross profit. If sustained, this combination could improve operating leverage and provide a stronger foundation for funding the pipeline over time.

Negative Factors

Persistent Large Net LossesThe company remains far from profitability despite stronger revenue and gross margin. A net loss of roughly $79.3M indicates that operating expenses continue to substantially exceed gross profit, making future earnings dependent on successful clinical progress, commercial scale, or additional financing.

Immutep Ltd (YP1B) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 29.47M
Dividend Yield: ―
Average Volume (3M): 17.79K
Price to Earnings (P/E): -0.5
Beta (1Y): 3.13
Revenue Growth: ―
EPS Growth: -24.80%
Country: Germany
Employees: 57
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Immutep Ltd Business Overview & Revenue Model

Company Description

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble...

Immutep Ltd Risk Analysis

Immutep Ltd disclosed 52 risk factors in its most recent earnings report. Immutep Ltd reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Immutep Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:YP1B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AU:MSB	70Outperform	AUD 2.71B	-30.92	-10.06%	―	555.67%	49.08%
AU:TLX	53Neutral	AUD 4.70B	97.04	7.24%	―	26.66%	179.32%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AU:RAD	42Neutral	AUD 18.84M	-0.26	-144.24%	―	-23.82%	12.36%
AU:SPL	40Underperform	AUD 197.99M	-24.85	-42.35%	―	145.32%	25.75%
AU:IMU	39Underperform	AUD 19.78M	-0.11	-414.10%	―	―	-2.15%

* Healthcare Sector Average

Performance Comparison

DE:YP1B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:YP1B	Immutep Ltd	0.01	-0.12	-90.08%
AU:IMU	Imugene Ltd	0.03	-0.28	-89.03%
AU:MSB	Mesoblast Limited	2.03	-0.28	-12.12%
AU:SPL	Starpharma Holdings Limited	0.42	0.02	5.20%
AU:TLX	Telix Pharmaceuticals Ltd.	14.02	-0.96	-6.41%
AU:RAD	Radiopharm Theranostics Limited	0.01	-0.01	-56.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Immutep Ltd AI Stock Analysis